Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant ChemoimmunotherapyToulsie Ramtohul, A. Tardivon, Enora Laas et al.|Radiology|2024Cited by 37
Prediction of pCR with pretreatment MRI radiomics in triple negative breast cancer treated with neoadjuvant chemo-immunotherapy.Toulsie Ramtohul, A. Tardivon, Victoire Lepagnay et al.|Journal of Clinical Oncology|2024Cited by 2
Abstract P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE)François‐Clément Bidard, Fatima Mechta-Grigoriou, Romain‐David Seban et al.|Clinical Cancer Research|2025Cited by 0